MX9604100A - Compuestos ciclicos, inhibidores de la adhesion. - Google Patents
Compuestos ciclicos, inhibidores de la adhesion.Info
- Publication number
- MX9604100A MX9604100A MX9604100A MX9604100A MX9604100A MX 9604100 A MX9604100 A MX 9604100A MX 9604100 A MX9604100 A MX 9604100A MX 9604100 A MX9604100 A MX 9604100A MX 9604100 A MX9604100 A MX 9604100A
- Authority
- MX
- Mexico
- Prior art keywords
- lys
- carbon atoms
- phe
- trace
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
El invento se refiere a nuevos ciclopéptidos de formula ciclo-(nArg-nGly-nAsp-nD-nE), en la que D y E, independientemente, representan Gly, Ala, Bala, Asn, Asp, Asp(OR), Arg, Cha, Cys, Gin, Glu, His, Ile, Leu, Lys, Lys(Ac), Lys(AcNH2), lys(AcSH), Met, Nal, Nle, Orn, Phe, 4-Hal-Phe, homo-Phe, Phg, Pro, Pya, Ser, Thr, Tia, Tic, Trp, Tyr o Val, pudiendo tratarse de derivados de estos aminoácidos; R representa alquilo de 1 a 18 átomos de C, aroílo de 7 a 11 átomos de C o arilalcanoílo de 8 a 12 átomos de C, y n significa que no hay sustituyentes o bien representa un resto de alquilo R, bencilo o un resto de arilalquilo de 7 a 18 átomos de C, unidos a la funcion alfa-amino del resto de aminoácido en cuestion; con la condicion de que al menos uno de los restos de aminoácidos presenta un sustituyente n, estando incluidas tanto las formas D como las formas L en caso de que los aminoácidos y restos de aminoácidos tengan actividad optica, y las sales inobjetables desde le punto de vista fisiologico de estos compuestos. Estos compuestos actuan como inhibidores de las integrinas y se pueden emplear en particular para prevenir y tratar enfermedades del sistema circulatorio, enfermedades angiogénicas, infecciones microbianas y para el tratamiento de tumores.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19534177A DE19534177A1 (de) | 1995-09-15 | 1995-09-15 | Cyclische Adhäsionsinhibitoren |
| DE19534177.5 | 1995-09-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MXPA96004100A MXPA96004100A (es) | 1997-08-01 |
| MX9604100A true MX9604100A (es) | 1997-08-30 |
Family
ID=7772215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9604100A MX9604100A (es) | 1995-09-15 | 1996-09-13 | Compuestos ciclicos, inhibidores de la adhesion. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6001961A (es) |
| EP (1) | EP0770622B1 (es) |
| JP (3) | JP4115550B2 (es) |
| KR (1) | KR100438244B1 (es) |
| CN (1) | CN1203090C (es) |
| AR (1) | AR003574A1 (es) |
| AT (1) | ATE189461T1 (es) |
| AU (1) | AU717574B2 (es) |
| BR (1) | BR9603751A (es) |
| CA (1) | CA2185489C (es) |
| CO (1) | CO4750841A1 (es) |
| CZ (1) | CZ286713B6 (es) |
| DE (2) | DE19534177A1 (es) |
| DK (1) | DK0770622T3 (es) |
| ES (1) | ES2144179T3 (es) |
| GR (1) | GR3033293T3 (es) |
| HU (1) | HU224614B1 (es) |
| ID (1) | ID18770A (es) |
| MX (1) | MX9604100A (es) |
| NO (1) | NO316946B1 (es) |
| PL (1) | PL185125B1 (es) |
| PT (1) | PT770622E (es) |
| RU (1) | RU2157379C2 (es) |
| SI (1) | SI0770622T1 (es) |
| SK (1) | SK282391B6 (es) |
| TR (1) | TR199600716A2 (es) |
| TW (1) | TW517064B (es) |
| UA (1) | UA49799C2 (es) |
| ZA (1) | ZA967768B (es) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
| US7053041B1 (en) * | 1996-05-31 | 2006-05-30 | The Scripps Research Institute | Methods and compositions useful for inhibition of αvβ5mediated angiogenesis |
| DE19613933A1 (de) * | 1996-04-06 | 1997-10-09 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| DK0951295T3 (da) * | 1996-05-31 | 2010-09-13 | Scripps Research Inst | Sammensætninger til anvendelse ved inhibering af alfa-v-beta3-medieret angiogenese |
| AU733303C (en) | 1996-05-31 | 2002-08-08 | Scripps Research Institute, The | Methods and compositions useful for inhibition of angiogenesis |
| CA2252629A1 (en) * | 1997-02-26 | 1998-09-03 | Toray Industries, Inc. | Remedies for hepatitis |
| DE19842415A1 (de) * | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
| BR9916536A (pt) | 1998-12-23 | 2002-01-02 | Searle & Co | Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação |
| US6521593B1 (en) * | 1999-02-01 | 2003-02-18 | Childrens Hospital Los Angeles | Methods for inhibiting brain tumor growth |
| PT1156823E (pt) * | 1999-02-12 | 2009-01-08 | Scripps Research Inst | Métodos para tratamento de tumores e metástases utilizando uma combinação de terapias anti-angiogénicas e imunitárias |
| UA71608C2 (en) * | 1999-03-11 | 2004-12-15 | Merck Patent Gmbh | A method for producing the cyclic pentapeptide |
| BR0011250A (pt) | 1999-06-01 | 2002-03-05 | Biogen Inc | Anticorpo monoclonal de bloqueio a vla-1 e seu uso para o tratamento de distúrbios inflamatórios |
| US6518244B2 (en) | 2000-03-09 | 2003-02-11 | Intimax Corporation | Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof |
| JP5054274B2 (ja) | 2000-11-01 | 2012-10-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 眼の疾患を治療するための方法および組成物 |
| US20040029788A1 (en) * | 2000-11-01 | 2004-02-12 | Hans-Markus Bender | Methods and compositions for the treatment of diseases of the eye |
| KR100983997B1 (ko) * | 2001-01-09 | 2010-09-28 | 메르크 파텐트 게엠베하 | 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를 사용하는 병용 요법 |
| AU2002258778C1 (en) * | 2001-04-13 | 2008-12-04 | Biogen Ma Inc. | Antibodies to VLA-1 |
| JP4660067B2 (ja) * | 2001-04-24 | 2011-03-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗血管新生剤とＴＮＦαとを用いる組合せ療法 |
| AU2003208833A1 (en) * | 2002-02-14 | 2003-09-04 | Merck Patent Gmbh | Methods and compositions for the treatment of eye diseases |
| DE10228049A1 (de) * | 2002-06-24 | 2004-01-15 | Merck Patent Gmbh | Flüssige Zubereitung enthaltend Oligopeptide |
| RS53476B (en) | 2003-07-18 | 2014-12-31 | Amgen Fremont Inc. | Hepatocyte Growth Factor Binders |
| DE10337863A1 (de) * | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Verwendung von Chromen-4-on-Derivaten |
| US9181303B2 (en) | 2005-12-22 | 2015-11-10 | Novabiotics Limited | Treatment of bacterial infections with cyclic antimicrobial peptides |
| PL1976863T3 (pl) * | 2005-12-22 | 2013-07-31 | Novabiotics Ltd | Cykliczne peptydy przeciwbakteryjne |
| US20080108664A1 (en) * | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| WO2007084670A2 (en) | 2006-01-18 | 2007-07-26 | Merck Patent Gmbh | Specific therapy using integrin ligands for treating cancer |
| ES2353482T3 (es) * | 2006-02-10 | 2011-03-02 | Amgen, Inc | Formas hidrato de amg706. |
| PT2034830E (pt) | 2006-05-25 | 2014-10-14 | Biogen Idec Inc | Anticorpos anti-vla-1 para o tratamento de acidentes vasculares cerebrais |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| DK2101805T3 (da) | 2007-01-18 | 2013-01-21 | Merck Patent Gmbh | Integrinligander til anvendelse i behandling af cancer |
| US20080241270A1 (en) * | 2007-03-30 | 2008-10-02 | Neal Robert A | Fluid composition for inhibiting surgical adhesion formation and related method of production |
| WO2008143933A1 (en) * | 2007-05-15 | 2008-11-27 | Cvpath Institute, Inc. | Coating stents with integrin selective peptides or mimetics |
| PL2167128T3 (pl) | 2007-07-17 | 2013-03-29 | Merck Patent Gmbh | Skonstruowane metodami inżynierii hybrydowe przeciwciała skierowane przeciwko integrynie alfa-v |
| GB0718957D0 (en) * | 2007-09-28 | 2007-11-07 | Ge Healthcare Ltd | Optical imaging agents |
| JP5718640B2 (ja) | 2007-08-21 | 2015-05-13 | アムジエン・インコーポレーテツド | ヒトｃ−ｆｍｓ抗原結合性タンパク質 |
| CN101990425B (zh) | 2008-04-08 | 2016-01-20 | 默克专利股份有限公司 | 包含环肽的组合物和使用方法 |
| EA020764B1 (ru) | 2008-12-23 | 2015-01-30 | Мерк Патент Гмбх | Биомаркеры для ингибиторов с антиангиогенной активностью |
| AU2010251385B2 (en) | 2009-05-20 | 2016-04-14 | Merck Patent Gmbh | Novel solid materials of {[2S, 5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them |
| US20120130146A1 (en) | 2009-05-25 | 2012-05-24 | Merck Patent Gmbh | Continuous administration of cilengitide in cancer treatments |
| EA022700B1 (ru) * | 2009-12-10 | 2016-02-29 | Мерк Патент Гмбх | Фармацевтическая композиция, содержащая олигопептиды |
| EP2407478A1 (en) | 2010-07-14 | 2012-01-18 | GENETADI Biotech, S.L. | New cyclotetrapeptides with pro-angiogenic properties |
| CN103153328A (zh) | 2010-07-16 | 2013-06-12 | 默克专利股份有限公司 | 肽在乳腺癌和/或骨转移灶的治疗中的用途 |
| WO2012016188A2 (en) * | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| WO2012069149A1 (en) | 2010-11-23 | 2012-05-31 | Merck Patent Gmbh | Solution comprising cyclic oligopeptides |
| SI2672994T1 (sl) | 2011-02-11 | 2018-09-28 | Merck Patent Gmbh | Protitelo proti alfa-v integrinu za zdravljenje raka prostate |
| WO2012110200A1 (en) | 2011-02-18 | 2012-08-23 | Merck Patent Gmbh | Cyclic peptide cyclo (l -arginyl - glycyl - l -aspartyl - d - phenylalanyl - n-methyl - l -valyl), compositions thereof, and use thereof in methods for treating graft -versus - host disease |
| WO2012146729A1 (en) * | 2011-04-29 | 2012-11-01 | Philipps-Universität Marburg | Lasso peptides as scaffolds for peptide grafting |
| JP2014516996A (ja) * | 2011-06-09 | 2014-07-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | キャリア中のシレンギチドの懸濁液による癌および転移の処置 |
| WO2013025939A2 (en) | 2011-08-16 | 2013-02-21 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| AU2013221635B2 (en) | 2012-02-16 | 2017-12-07 | Santarus, Inc. | Anti-VLA1 (CD49a) antibody pharmaceutical compositions |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| EP2890696A1 (en) | 2012-08-29 | 2015-07-08 | Amgen, Inc. | Quinazolinone compounds and derivatives thereof |
| JP6215335B2 (ja) | 2013-09-24 | 2017-10-18 | 富士フイルム株式会社 | 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体 |
| MX2017012184A (es) | 2015-03-25 | 2018-01-09 | Fujifilm Corp | Metodo para manufacturar compuesto novedoso que contiene nitrogeno o sal del mismo e intermediario de manufacturacion del compuesto novedoso que contiene nitrogeno o sal del mismo. |
| EP3365353B1 (en) * | 2015-10-23 | 2023-11-22 | Universiteit Twente | Integrin binding peptides and uses thereof |
| US20190144547A1 (en) | 2015-11-23 | 2019-05-16 | Merck Patent Gmbh | Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders |
| EP3207937A1 (en) | 2016-02-17 | 2017-08-23 | Royal College of Surgeons in Ireland | A method of treating or preventing sepsis |
| HUE056777T2 (hu) | 2016-12-22 | 2022-03-28 | Amgen Inc | Benzizotiazol-, izotiazolo[3,4-b]piridin-, kinazolin-, ftálazin-, pirido[2,3-d]piridazin- és pirido[2,3-d]pirimidin-származékok mint KRAS G12C inhibitorok tüdõ-, hasnyálmirigy- vagy vastagbélrák kezelésére |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| JP7150823B2 (ja) | 2017-09-08 | 2022-10-11 | アムジエン・インコーポレーテツド | ＫＲａｓ Ｇ１２Ｃの阻害剤及びそれを使用する方法 |
| US11090304B2 (en) | 2018-05-04 | 2021-08-17 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| JP7361722B2 (ja) | 2018-05-04 | 2023-10-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法 |
| EP3790886A1 (en) | 2018-05-10 | 2021-03-17 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
| WO2019232419A1 (en) | 2018-06-01 | 2019-12-05 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| CA3099799A1 (en) | 2018-06-11 | 2019-12-19 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
| AU2019336588B2 (en) | 2018-06-12 | 2022-07-28 | Amgen Inc. | KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer |
| JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| CA3117222A1 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| EP3897855B1 (en) | 2018-12-20 | 2023-06-07 | Amgen Inc. | Kif18a inhibitors |
| WO2020132653A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| EP3897852A1 (en) | 2018-12-20 | 2021-10-27 | Amgen Inc. | Kif18a inhibitors |
| CA3130083A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| SG11202112855WA (en) | 2019-05-21 | 2021-12-30 | Amgen Inc | Solid state forms |
| AU2020325115A1 (en) | 2019-08-02 | 2022-03-17 | Amgen Inc. | Pyridine derivatives as KIF18A inhibitors |
| WO2021026101A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| AU2020381492A1 (en) | 2019-11-14 | 2022-05-26 | Amgen Inc. | Improved synthesis of KRAS G12C inhibitor compound |
| JP2023509701A (ja) | 2020-01-07 | 2023-03-09 | レヴォリューション・メディスンズ，インコーポレイテッド | Ｓｈｐ２阻害剤投薬およびがんを処置する方法 |
| WO2021224234A1 (en) | 2020-05-04 | 2021-11-11 | Helmholtz-Zentrum für Infektionsforschung GmbH | Antiviral use of cilengitide |
| KR20230067635A (ko) | 2020-09-15 | 2023-05-16 | 레볼루션 메디슨즈, 인크. | 암의 치료에서 ras 억제제로서 인돌 유도체 |
| US20240082347A1 (en) | 2021-01-22 | 2024-03-14 | Royal College Of Surgeons In Ireland | Treatment of coronavirus |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4517686A (en) * | 1982-08-04 | 1985-05-21 | La Jolla Cancer Research Foundation | Polypeptide |
| US4578079A (en) * | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
| US4589881A (en) * | 1982-08-04 | 1986-05-20 | La Jolla Cancer Research Foundation | Polypeptide |
| US4792525A (en) * | 1982-08-04 | 1988-12-20 | La Jolla Cancer Research Foundation | Tetrapeptide |
| US4508921A (en) * | 1984-06-28 | 1985-04-02 | Merck & Co., Inc. | Process for preparation of alpha-alkyl amino acids |
| JP2945680B2 (ja) * | 1988-09-09 | 1999-09-06 | 旭硝子株式会社 | ペプチド誘導体およびその用途 |
| DE4310643A1 (de) * | 1993-04-01 | 1994-10-06 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
-
1995
- 1995-09-15 DE DE19534177A patent/DE19534177A1/de not_active Withdrawn
-
1996
- 1996-08-31 SI SI9630172T patent/SI0770622T1/xx unknown
- 1996-08-31 ES ES96113972T patent/ES2144179T3/es not_active Expired - Lifetime
- 1996-08-31 PT PT96113972T patent/PT770622E/pt unknown
- 1996-08-31 EP EP96113972A patent/EP0770622B1/de not_active Expired - Lifetime
- 1996-08-31 DK DK96113972T patent/DK0770622T3/da active
- 1996-08-31 DE DE59604363T patent/DE59604363D1/de not_active Expired - Lifetime
- 1996-08-31 AT AT96113972T patent/ATE189461T1/de active
- 1996-09-10 CZ CZ19962643A patent/CZ286713B6/cs not_active IP Right Cessation
- 1996-09-10 AU AU65580/96A patent/AU717574B2/en not_active Ceased
- 1996-09-12 ID IDP962581A patent/ID18770A/id unknown
- 1996-09-12 TR TR96/00716A patent/TR199600716A2/xx unknown
- 1996-09-12 SK SK1167-96A patent/SK282391B6/sk not_active IP Right Cessation
- 1996-09-12 CN CNB961125934A patent/CN1203090C/zh not_active Expired - Fee Related
- 1996-09-13 HU HU9602507A patent/HU224614B1/hu not_active IP Right Cessation
- 1996-09-13 JP JP26372596A patent/JP4115550B2/ja not_active Expired - Fee Related
- 1996-09-13 RU RU96118225/14A patent/RU2157379C2/ru not_active IP Right Cessation
- 1996-09-13 MX MX9604100A patent/MX9604100A/es not_active IP Right Cessation
- 1996-09-13 UA UA96093558A patent/UA49799C2/uk unknown
- 1996-09-13 NO NO19963853A patent/NO316946B1/no not_active IP Right Cessation
- 1996-09-13 PL PL96316071A patent/PL185125B1/pl not_active IP Right Cessation
- 1996-09-13 ZA ZA967768A patent/ZA967768B/xx unknown
- 1996-09-13 CO CO96048991A patent/CO4750841A1/es unknown
- 1996-09-13 BR BR9603751A patent/BR9603751A/pt not_active IP Right Cessation
- 1996-09-13 AR ARP960104340A patent/AR003574A1/es active IP Right Grant
- 1996-09-13 CA CA002185489A patent/CA2185489C/en not_active Expired - Fee Related
- 1996-09-14 KR KR1019960039979A patent/KR100438244B1/ko not_active IP Right Cessation
- 1996-09-16 US US08/694,387 patent/US6001961A/en not_active Expired - Lifetime
- 1996-09-16 TW TW085111375A patent/TW517064B/zh not_active IP Right Cessation
-
2000
- 2000-04-21 GR GR20000400975T patent/GR3033293T3/el unknown
-
2006
- 2006-08-30 JP JP2006234221A patent/JP2007016042A/ja not_active Withdrawn
-
2007
- 2007-03-23 JP JP2007077893A patent/JP4116062B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9604100A (es) | Compuestos ciclicos, inhibidores de la adhesion. | |
| TW343198B (en) | Cyclopeptides useful as adhesion inhibitors, process for the preparation thereof, and pharmaceutical composition containing them | |
| EP1225168B8 (en) | Prostaglandin-F-2 alpha derivative for the treatment of glaucoma or ocular hypertension | |
| IL125711A0 (en) | Human metabotropic glutamate receptor | |
| NL300013I1 (nl) | Nieuwe protein met TNF-remmende werking en hun ber | |
| MX9703643A (es) | Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana. | |
| KR900002801A (ko) | 당뇨병 치료용 약학적제제 | |
| AU6020099A (en) | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein | |
| MY131805A (en) | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis. | |
| MX9703642A (es) | Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana. | |
| US20120220525A1 (en) | Stablized Melanocortin Ligands | |
| AU5362190A (en) | Novel peptides, and antidementia agents containing the same | |
| NO952336L (no) | Insulin analoger | |
| NO941151L (no) | Lineære adhesjonsinhibitorer | |
| KR930002373A (ko) | 헥사펩티드 | |
| CA2096933A1 (en) | Compounds and compositions which inhibit bone resorption | |
| HUP0003357A2 (hu) | Angiogén hatású ciklusos azapeptidek, ezeket hatóanyagként tartalmazó gyógyászati készítmények, eljárás ezek előállítására és alkalmazásuk | |
| RU96123269A (ru) | Три-, тетра-, пента- и полипептиды и их терапевтическое применение в качестве антидепрессивного агента | |
| YU48997A (sh) | Novi biološki aktivni proteini, njihove farmaceutske smeše i postupak za njihovo dobijanje | |
| KR880013902A (ko) | 아미노산 유도체 | |
| KR950011466A (ko) | 선형 결합 억제제 | |
| KR890009974A (ko) | 신규 화합물들 | |
| KR940011479A (ko) | 시클로 펩티드 | |
| KR880006262A (ko) | 펩티드 | |
| WO2024031084A3 (en) | Compositions and methods for dye-bound cyclized peptides for medical use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| MM | Annulment or lapse due to non-payment of fees |